Complement Inhibitors Ravulizumab and Eculizumab Impact Measures of Neuroaxonal Damage
Neurology Live,
In an analysis of the phase 3 PREVENT (NCT01892345) and CHAMPION-NMOSD trials (NCT04201262), findings showed that both…
In an analysis of the phase 3 PREVENT (NCT01892345) and CHAMPION-NMOSD trials (NCT04201262), findings showed that both…
This article was originally published here J Neuroinflammation. 2021 May 1;18(1):105.